

Coronavirus occurrence and transmission over 8 years in the HIVE cohort of households in Michigan

Arnold S. Monto, Peter DeJonge, Amy P. Callear, Latifa A. Bazzi, Skylar Capriola, Ryan E. Malosh, Emily T. Martin, Joshua G. Petrie

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI

CORRESPONDING AUTHOR: Arnold S. Monto

University of Michigan School of Public Health

1415 Washington Heights

Ann Arbor, MI 48109

734-764-5453

asmonto@umich.edu

ABSTRACT

BACKGROUND

As part of the Household Influenza Vaccine Evaluation (HIVE) study, acute respiratory infections (ARI) have been identified in children and adults over 8 years.

METHODS

Annually, 890 to 1441 individuals were followed and contacted weekly to report ARIs. Specimens collected during illness were tested for human coronaviruses (HCoV) types OC43, 229E, HKU1, and NL63.

RESULTS

In total, 993 HCoV infections were identified over 8 years, with OC43 most commonly seen and 229E the least. HCoVs were detected in a limited time period, between December and April/May, and peaked in January/February. Highest infection frequency was in children <5 years (18 per 100 person-years), with little variation in older age groups (range: 7 to 11 per 100 person-years). Overall, 9% of adult cases and 20% of cases in children were associated with medical consultation. Of the 993 infections, 260 were acquired from an infected household contact. The serial interval between index and household-acquired cases ranged from 3.2 to 3.6 days and the secondary infection risk ranged from 7.2% to 12.6% by type.

21 CONCLUSIONS

22 Coronaviruses are sharply seasonal. They appear, based on serial interval and
23 secondary infection risk, to have similar transmission potential to influenza A(H3N2) in
24 the same population.

Accepted Manuscript

Coronaviruses, long known to infect a wide variety of species, have been recognized as human respiratory pathogens for more than 60 years.¹⁻³ While animal coronaviruses have been associated with severe disease in their respective hosts, human coronaviruses (HCoV) were historically detected in mild respiratory illnesses.⁴⁻⁶ Therefore, the identification of Severe Acute Respiratory Syndrome (SARS) as caused by a coronavirus of animal origin in 2002 was a surprise because of its epidemic behavior as well as its severity.^{7,8} Also a surprise was ultimate interruption of SARS transmission by public health measures.⁹ In 2012, another novel coronavirus of animal origin emerged as the causative agent of Middle East Respiratory Syndrome (MERS).¹⁰ Unlike SARS, human-to-human transmission of MERS has been limited and sporadic cases have continued to occur primarily in Saudi Arabia among those with contact with camels.¹¹ The current outbreak of a novel coronavirus (SARS-CoV-2) has focused attention back to this often forgotten and unstudied group of pathogens.¹²

HCoVs were first recognized when specimens from individuals ill with respiratory illnesses were inoculated into organ cultures. One of these viruses is now known as OC (organ culture) 43.¹³ Another virus, 229E was first grown in primary human kidney culture.¹⁴ Because of the difficulties in isolating them, much of the initial work in understanding their occurrence in was done by serology.^{15,16} Following renewed interest after the SARS epidemic, two additional coronaviruses, HKU1 and NL63, were identified in the 2000's, first from persons with severe respiratory illnesses.¹⁷⁻²⁰

Availability of reverse-transcriptase polymerase chain reaction (RT-PCR) has now made it possible to detect infection easily for each of the 4 known human coronaviruses. However, as data from population-based studies using molecular methods have

accumulated, minimal attention has been paid to these viruses, perhaps because there was so little known about their role in respiratory illnesses. The Household Influenza Vaccine Evaluation (HIVE) study is a longitudinal investigation of respiratory illnesses in households with children in the Ann Arbor, Michigan area that has been ongoing since 2010. Here we report on the occurrence of the 4 HCoV types over an 8 year period.

METHODS

Study Population

The complete methods of the HIVE cohort have been published previously.²¹ Households were recruited from local households receiving primary care from the University of Michigan Health Care System. From 2010-2011 through 2015-2016, eligible households were those with 4 or more members at least 2 of whom were less than 18 years old. In subsequent years, eligible households contained 3 or more members including at least one child under 5 years (2016-2017) or under 10 years (2017-2018). Each year in the spring or summer, households attended an enrollment or re-engagement visit to collect or update the demographic characteristics for each participant and household. Adult household members provided informed consent for themselves and their children, and children 7 years or older also provided verbal assent prior to participating. This study was reviewed and approved by the institutional review board at the University of Michigan Medical School.

Acute Respiratory Illness Surveillance

HIVE participants were instructed to report the onset of two or more acute respiratory illness (ARI) symptoms from anyone in the household, including: cough, fever or

70 feverishness, nasal congestion, chills, headache, body aches, or sore throat. Weekly
71 email and phone contacts were used to confirm the presence or absence of ARI in the
72 household. Beginning in 2014-2015 a separate set of age-specific symptom qualifiers
73 were provided for participants under 3 years of age, including: cough,
74 fever/feverishness, nasal congestion, trouble breathing, fussiness, decreased appetite,
75 and fatigue. Ill participants with 2 or more of the above symptoms attended an illness
76 visit within 7 days of illness onset where study staff interviewed them about their illness
77 and collected nasal and throat swabs (nasal only in children <3 years) combined in a
78 single vial of viral transport media. Study staff followed up with ill participants
79 approximately a week after their illness visit to collect additional information about the
80 course of the illness including participant report of whether they contacted a healthcare
81 provider regarding their illness.

82 Prior to the 2014-15 season, HIVE ARI surveillance periods were seasonal based on
83 the likely influenza season. For the first 4 study years, the annual surveillance periods
84 were October 1, 2010 through April 30, 2011; December 1, 2011 through May 10, 2012;
85 October 1, 2012 through May 13, 2013; and October 1, 2013 through April 30, 2014.
86 Surveillance resumed on October 1, 2014 and has been operating year-round since
87 then. New surveillance years are designated beginning July 1 and lasting until June 30
88 of the subsequent year.

89 *Laboratory Testing*

90 Respiratory specimens collected at illness visits were tested for detection of respiratory
91 viruses, including the four seasonal coronavirus types (229E, OC43, HKU1, and NL63).

For specimens collected prior to the 2016-2017 study year, testing was performed by singleplex RT-PCR using primers and probes developed by the CDC Division of Viral Diseases, Gastroenteritis, and Respiratory Viruses.²² Specimens collected in the 2016-2017 and 2017-2018 years were tested using the FTD Respiratory Pathogen 33 multiplex PCR kit (Fast Track Diagnostics, Luxembourg).

Statistical Analysis

Seasonal case counts of HCoV 229E, HKU1, NL63, and OC43 were used to assess annual patterning of each type; counts were also summed by month across all seasons combined to assess broad seasonality by type. Illnesses with multiple, coincident HCoV detections were only counted once in analyses of overall HCoV infections, but each HCoV type involved in coincident detection was also included in type-specific analyses.

Type-specific coronavirus incidence and corresponding 95% confidence intervals were calculated by age group (<5, 6-11, 12-17, 18-49, and ≥50 years) and by study year. Incidence was calculated as the number of type-specific coronavirus infections divided by the total participant-time included during a specified time period. Because the majority of the HCoV season was captured even in study years without year-round surveillance, all participants were treated as contributing a full year of person time for each study year in which they were enrolled.

For each study year, we defined household index cases as the first person in a household to develop ARI with HCoV detection. Secondary cases were defined as those who developed ARI with HCoV detection within 14 days following illness in a household contact with the same type. The serial interval was calculated as the average

number of days from the illness onset a household index case to the illness onset of secondary cases. Secondary infection risks were calculated as the proportion of household contacts exposed to an index case who developed secondary infection. For the purpose of these transmission analyses, only the first introduction of HCoV to a household were considered.

We used latent class analysis to identify and compare classes of illness severity of HCoV infection across age groups and the four HCoV types (Supplementary Materials). For the latent items, we identified seven participant-reported potential markers of illness severity including illness symptoms (cough, fever, fatigue, wheezing, and dyspnea), missed work or school, and medically-attended illness (phone consultation, outpatient care, and inpatient care). A priori, we anticipated three latent classes of severity to represent mild, moderate, and severe illness; model diagnostics also confirmed that a three-class model was most parsimonious. Latent class groups were then assigned to each HCoV infection, not including cases with multiple coincident HCoV types detected. Age-adjusted multinomial logistic regression models were then used to compare the odds of being assigned to each latent class between the four HCoV types.

RESULTS

Characteristics of the study population

The number of individuals under study ranged from 895 to 1441, and the number of households ranged from 209 to 340 over the 8 years (Table 1). Because of the requirement that children be present in the household, the studied population tended to be young, with relative absence of older adults. The numbers in the cohort varied from

year to year but the age structure remained similar in all years, due to combined retention of existing households and recruitment of new households with young children.

The number of ARIs reported also varied from year to year, mainly related to the number of individuals on report but also the differential occurrence of influenza and other respiratory viruses (Table 1). Overall, from 2010-11 through 2017-18, 7992 ARI cases were reported to HIVE; 7469 had an illness visit with specimen collection and were tested for respiratory virus detection (93%). The proportion of ARIs associated with coronavirus identification varied between 8.3% during the major influenza year 2014-2015 to 16.3% in 2012-2013. Co-detection of multiple coronavirus types ranged from 0.7% of all coronavirus ARIs in 2010-2011 to 14.2% in 2014-2015.

Variation in identifying the four coronaviruses by seasons and years.

There was distinct seasonality in the identifications of the viruses. In the first 5 of the 8 years, no surveillance was conducted from June to September. When year-round surveillance was in place in the 2015-2016 through 2017-2018 study years, only 9 (2.5%) of the total 364 coronavirus-associated ARI occurred from June through September. Combined over the 8 years, the number of identifications for each virus increased in December, peaked in January or February, and began to decrease in March (Figure 1). The seasonal similarity between the 4 types is striking, with only the peak aggregate month differing between January and February.

Identification of each of the four coronaviruses types occurred in each of the 8 study years, except for 2016-17, when no HKU1 viruses were identified (Table 1, Figure 2). In

prior community studies^{16,23–25}, there were suggestions of a cycling between 229E and OC43, with major years followed by lesser years. Such a pattern appears to be present for all types where relatively high incidence is not seen in consecutive years for a specific type. Likewise, combinations of co-circulating types were not found to be consistent from year to year.

Occurrence of infections by age and illness characteristics

Infection rates for common respiratory pathogens are highest in young children and usually fall off with increasing age. With the exception of 229E, where incidence per 100 person-years was relatively low and did not vary by age, the incidence was consistently highest among children less than 5 years (Figure 3). Among those older than 5 years, incidence was relatively flat with little consistent variation with increase in age.

Illness severity and outcomes

Overall, 9% of adult cases and 20% of cases in children were associated with medical consultation. However, medical consultation only captures one facet of overall illness severity. Therefore, we used latent class analysis to categorize coronavirus case severity based on participant-reported symptoms and actions taken during the course of their illness (Supplemental Materials). Mild illnesses were primarily characterized by cough and fatigue, those with moderate illnesses were additionally likely to have fever and to miss school or work, and those with severe illness additionally were likely to have wheezing, dyspnea, or to seek care for their illness. Of all single coronavirus detections, 59% were categorized as mild illness by latent class methods. Moderate and severe illness were noted in 31% and 10% of coronavirus detections, respectively. HCoV

illnesses in children less than 5 years and adults older than 50 years were most likely to be classified as severe. In age-adjusted multinomial regression models (Table 2), 229E was associated with significantly higher odds of severe illness (versus mild) compared to the three other HCoV types (OR: 1.82, 95%CI: 1.01-3.27). On the other hand, NL63 was associated with significantly lower odds of severe illness (versus mild) compared to the other three types (OR: 0.59, 95%CI: 0.35-0.99).

Household transmission

Households present an ideal setting for determining the transmission characteristics of respiratory viruses. Of the 993 HCoVs identified, 260 occurred within 14 days of exposure to a household contact infected with the same type. The secondary attack risk was 7.2% for 229E, 8.6% for HKU1, 10.6% for OC43, and 12.6% for NL63. The average serial interval between the onset of illness in the household index case and onset of illness in secondary cases was similar across (3.2 days for NL63 and HKU1, 3.3 days for OC43, and 3.6 days for 229E). Consistent with overall patterns of incidence by age (Figure 3), index cases were most frequently children with the exception of 229E where adults 18 to 49 years were responsible for nearly half of the household introductions (Table 3).

DISCUSSION

While HCoVs have been recognized for many years to be a cause of common respiratory illnesses, documentation of their involvement has lagged behind that of other agents, such as the rhinoviruses. This includes frequency of infection, illnesses produced and transmission characteristics. We might not even know about the

existence of the two most recently identified viruses, NL63 and HKU1, if attention had not been directed to HCoV following the occurrence of SARS. The development of the RT-PCR test and the inclusion of the 4 types of HCoV in multiplex clinical testing panels, mainly used in handling severe illnesses such as pneumonia, have resulted in numerous reports of the involvement of these viruses in hospitalizations. While studies of hospitalized patients have established the role of HCoV in causing lower respiratory illness and the global circulation of these viruses, they are unable to shed light on the frequency or seasonality of these viruses in the broader community. There are a few exceptions which have followed HCoV infections over longer periods often in special population groups. In particular, a recent study covered 9 years of Norwegian children hospitalized with respiratory infection and found that coronaviruses were involved in 9.1% of episodes.²⁶ The highest frequencies were in young children, similar to the infection rates demonstrated in the current study and also identical to it was the ordering of frequency of types involved with OC43 the most common and 229E the least. While the authors did not emphasize seasonality, it was clear that most of the infections occurred in the winter months.

The regular appearance of all types of coronaviruses in the same months with minimal circulation in the summer was a clear finding of this study. Unlike the influenza viruses which peak at different times during the colder season from year to year and even the rhinoviruses which are most common in the autumn and spring but are present year round, the coronaviruses are sharply seasonal with little spread after May until November or December. Our findings, on a larger scale, expand on the results a two year study in childcare attendees suggesting a similar seasonal pattern.²⁷ It is of interest

that the SARS coronavirus outbreaks occurred during the same time period, with the end of global outbreaks in the period of May-June 2003.²⁸ Whether such a time table applies to the current circulation of SARS-CoV-2 is impossible to determine at this time.

Another notable finding in this community study was the fact that, in those above 4 years of age, HCoV infection rates were relatively consistent. Most agents causing lower respiratory infections typically have falling incidence with increasing age, sometimes with an increase in young adults.²⁹ However, it is clear that like other respiratory viruses, HCoV infect people of all ages and infection only produces relative immunity. The type-specificity of the protection is also not completely clear; although frequent co-circulation of types and co-detection within individuals suggests that protection is likely not highly cross-reactive. As with SARS and MERS, SARS-CoV-2 has most frequently infected adults to date.³⁰ Whether the relative sparing of children has largely been driven by contact and exposure patterns or other factors remains unclear. However, the frequency of infection in adults suggests that there is likely little cross-protective immunity from prior seasonal HCoV infection.

The MERS coronavirus is limited in its potential for human to human transmission except in the nosocomial setting.¹¹ Although the SARS coronavirus more effectively transmitted human to human, transmission was interrupted by public health interventions.³¹ The seasonal HCoV viruses are clearly different in their transmission characteristics given their continued seasonal circulation year after year. The serial interval between cases and the secondary infection risk in the HIVE cohort was similar to that previously found for A(H3N2).³² Our secondary attack rates may reflect the smaller household structure found in our region. A longitudinal study in Kenya found

overall attack rates as high as 34.0% over one season in a study of households of sizes ranging to 37 members.³³

The transition from pandemic to seasonal circulation is well established for influenza, wherein, following an influenza pandemic, the novel virus becomes the new seasonal virus, replacing the previous A subtype.³⁴ The four current HCoVs have been circulating for decades, and it is unclear how they initially emerged or whether they replaced previously circulating viruses.³⁵ Contrary to influenza, MERS and SARS, have not become a fixed presence in seasonal respiratory illness circulation on a global scale. Only time will tell if SARS-CoV-2 will become a continuing presence in the seasonal HCoV landscape, continue with limited circulation as with MERS, or like SARS, disappear from humans altogether.

261 *Financial support.* This work was supported by the National Institute of Allergy and
262 Infectious Diseases (R01 AI097150, R56 AI097150).

263 *Potential conflicts of interest.* All authors report no conflicts of interest relevant to this
264 article.

Accepted Manuscript

REFERENCES

1. Tyrrell DAJ, Bynoe ML. Cultivation of a Novel Type of Common-cold Virus in Organ Cultures. *Br Med J* 1965;1(5448):1467–70.
2. Hamre D, Procknow JJ. A new virus isolated from the human respiratory tract. *Proc Soc Exp Biol Med Soc Exp Biol Med N Y N* 1966;121(1):190–3.
3. McIntosh K, Dees JH, Becker WB, Kapikian AZ, Chanock RM. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. *Proc Natl Acad Sci U S A* 1967;57(4):933–40.
4. Hamre D, Beem M. VIROLOGIC STUDIES OF ACUTE RESPIRATORY DISEASE IN YOUNG ADULTS. CORONAVIRUS 229E INFECTIONS DURING SIX YEARS OF SURVEILLANCE. *Am J Epidemiol* 1972;96(2):94–106.
5. McIntosh K, Kapikian AZ, Turner HC, Hartley JW, Parrott RH, Chanock RM. SEROEPIDEMIOLOGIC STUDIES OF CORONAVIRUS INFECTION IN ADULTS AND CHILDREN. *Am J Epidemiol* 1970;91(6):585–92.
6. Saif LJ. Animal coronaviruses : what can they teach us about the severe acute respiratory syndrome? 2004;23(2):643–60.
7. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med* 2003;348(20):1967–76.
8. Peiris J, Lai S, Poon L, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. *The Lancet* 2003;361(9366):1319–25.
9. Pacific WHORO for the W. SARS : how a global epidemic was stopped [Internet]. Manila : WHO Regional Office for the Western Pacific; 2006 [cited 2020 Feb 20]. Available from: <https://apps.who.int/iris/handle/10665/207501>
10. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med* 2012;367(19):1814–20.
11. Hui DS, Azhar EI, Kim Y-J, Memish ZA, Oh M, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. *Lancet Infect Dis* 2018;18(8):e217–27.
12. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020;

13. Brucková M, McIntosh K, Kapikian AZ, Chanock RM. The adaptation of two human coronavirus strains (OC38 and OC43) to growth in cell monolayers. *Proc Soc Exp Biol Med Soc Exp Biol Med N Y N* 1970;135(2):431–5.
14. Hamre D, Kindig DA, Mann J. Growth and Intracellular Development of a New Respiratory Virus. *J Virol* 1967;1(4):810–6.
15. Cavallaro JJ, Monto AS. Community-wide Outbreak of Infection with a 229E-like Coronavirus in Tecumseh, Michigan. *J Infect Dis* 1970;122(4):272–9.
16. Monto AS, Lim SK. The Tecumseh Study of Respiratory Illness. VI. Frequency of and Relationship between Outbreaks of Coronavims Infection. *J Infect Dis* 1974;129(3):271–6.
17. Guan Y, Zheng BJ, He YQ, et al. Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China. *Science* 2003;302(5643):276–8.
18. van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. *Nat Med* 2004;10(4):368–73.
19. Fouchier RAM, Hartwig NG, Bestebroer TM, et al. A previously undescribed coronavirus associated with respiratory disease in humans. *Proc Natl Acad Sci* 2004;101(16):6212–6.
20. Woo PCY, Lau SKP, Chu C, et al. Characterization and Complete Genome Sequence of a Novel Coronavirus, Coronavirus HKU1, from Patients with Pneumonia. *J Virol* 2005;79(2):884–95.
21. Monto AS, Malosh RE, Evans R, et al. Data resource profile: Household Influenza Vaccine Evaluation (HIVE) Study. *Int J Epidemiol* 2019;48(4):1040–1040g.
22. Sakthivel SK, Whitaker B, Lu X, et al. Comparison of fast-track diagnostics respiratory pathogens multiplex real-time RT-PCR assay with in-house singleplex assays for comprehensive detection of human respiratory viruses. *J Virol Methods* 2012;185(2):259–66.
23. Kaye HS, Dowdle WR. SEROEPIDEMIOLOGIC SURVEY OF CORONAVIRUS (STRAIN 229E) INFECTIONS IN A POPULATION OF CHILDREN. *Am J Epidemiol* 1975;101(3):238–44.
24. Hendley JO, Fishburne HB, Gwaltney JM. Coronavirus Infections in Working Adults. *Am Rev Respir Dis* 1972;105(5):805–11.

25. Hovi T, Kainulainen H, Ziola B, Salmi A. OC43 strain-related coronavirus antibodies in different age groups. *J Med Virol* 1979;3(4):313–20.
26. Heimdal I, Moe N, Krokstad S, et al. Human Coronavirus in Hospitalized Children With Respiratory Tract Infections: A 9-Year Population-Based Study From Norway. *J Infect Dis* 2019;219(8):1198–206.
27. Fairchok MP, Martin ET, Chambers S, et al. Epidemiology of viral respiratory tract infections in a prospective cohort of infants and toddlers attending daycare. *J Clin Virol* 2010;49(1):16–20.
28. Ofner-Agostini M, Wallington T, Henry B, et al. Investigation of the second wave (phase 2) of severe acute respiratory syndrome (SARS) in Toronto, Canada. What happened? *Can Commun Dis Rep Relev Mal Transm Au Can* 2008;34(2):1–11.
29. Monto AS, Malosh RE, Petrie JG, Thompson MG, Ohmit SE. Frequency of Acute Respiratory Illnesses and Circulation of Respiratory Viruses in Households With Children Over 3 Surveillance Seasons. *J Infect Dis* 2014;210(11):1792–9.
30. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med* 2020;
31. Lipsitch M, Cohen T, Cooper B, et al. Transmission Dynamics and Control of Severe Acute Respiratory Syndrome. *Science* 2003;300(5627):1966–70.
32. Petrie JG, Ohmit SE, Cowling BJ, et al. Influenza transmission in a cohort of households with children: 2010–2011. *PloS One* 2013;8(9):e75339.
33. Munywoki PK, Koech DC, Agoti CN, Cane PA, Medley GF, Nokes DJ. Continuous Invasion by Respiratory Viruses Observed in Rural Households During a Respiratory Syncytial Virus Seasonal Outbreak in Coastal Kenya. *Clin Infect Dis* 2018;67(10):1559–67.
34. Monto AS, Fukuda K. Lessons from Influenza Pandemics of the last 100 Years. *Clin Infect Dis Off Publ Infect Dis Soc Am* 2019;
35. Talbot HK, Shepherd BE, Crowe JEJ, et al. The Pediatric Burden of Human Coronaviruses Evaluated for Twenty Years. *Pediatr Infect Dis J* 2009;28(8):682–687.

Table 1: Characteristics of the study population and counts of human coronavirus infections by study year: Household Influenza Vaccine Evaluation (HIVE) cohort 2010 – 2018.

	Season							
	2010-2011	2011-2012	2012-2013	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018
Surveillance period	Oct 1 – Apr 30	Dec 1 – May 10	Oct 1 – May 13	Oct 1 – Apr 30	Oct 1 – Jun 30	Jul 1 – Jun 30	Jul 1 – Jun 30	Jul 1 – Jun 30
Households enrolled	328	213	321	232	340	227	209	293
Participants enrolled	1441	943	1426	1049	1431	996	895	1189
Age groups								
0-5	250 (17.4)	131 (13.9)	225 (15.8)	133 (12.7)	205 (14.3)	97 (9.7)	117 (13.1)	220 (18.5)
6-11	382 (26.5)	278 (29.5)	401 (28.1)	316 (30.1)	445 (31.1)	327 (32.8)	257 (28.7)	298 (25.1)
12-17	208 (14.4)	141 (15.0)	208 (14.6)	169 (16.1)	212 (14.8)	173 (17.4)	150 (16.8)	166 (14.0)
18-49	546 (37.9)	353 (37.4)	536 (37.6)	385 (36.7)	512 (35.8)	351 (35.2)	332 (37.1)	457 (38.4)
50+	55 (3.8)	40 (4.2)	56 (3.9)	46 (4.4)	57 (4.0)	48 (4.8)	39 (4.4)	48 (4.0)
ARI reports	1028	417	1227	706	1362	934	847	1401
HCoV positive cases, N (% of all ARI cases)								
All Types ^a	152 (14.8)	59 (14.1)	200 (16.3)	105 (14.9)	113 (8.3)	109 (11.7)	112 (13.2)	143 (10.2)
229E	7 (0.7)	20 (4.8)	8 (0.7)	45 (6.4)	8 (0.6)	3 (0.3)	46 (5.4)	12 (0.9)
HKU1	28 (2.7)	19 (4.6)	17 (1.4)	30 (4.2)	14 (1)	36 (3.9)	0 (0)	49 (3.5)
NL63	62 (6)	14 (3.4)	75 (6.1)	21 (3)	37 (2.7)	40 (4.3)	11 (1.3)	63 (4.5)
OC43	56 (5.4)	13 (3.1)	113 (9.2)	16 (2.3)	71 (5.2)	34 (3.6)	58 (6.8)	26 (1.9)

^a Individual types sum to more than all types because coinfections were counted in each type, but only included as single cases in counts of all types.

Abbreviation: HCoV, human coronavirus.

Table 2. Odds Ratios and 95% confidence intervals from multinomial logistic regression models predicting illness severity from human coronavirus type and age group.

HCoV Type	Severity Group				
	Odds Ratio (95% Confidence Interval) ^a				
	Mild	Moderate		Severe	
229E	ref	1.51	(1.00, 2.29)	1.82	(1.01, 3.27)
HKU1	ref	1.13	(0.77, 1.66)	1.51	(0.88, 2.59)
NL63	ref	0.88	(0.65, 1.20)	0.59	(0.35, 0.99)
OC43	ref	0.84	(0.62, 1.13)	0.87	(0.55, 1.37)
Age Group					
0 to 5 years	ref	1.46	(1.04, 2.04)	2.06	(1.27, 3.33)
6 to 11 years	ref	1.53	(1.11, 2.11)	1.02	(0.60, 1.72)
12 to 17 years	ref	0.99	(0.62, 1.61)	0.71	(0.31, 1.62)
18 to 49 years	ref	0.55	(0.40, 0.74)	0.59	(0.37, 0.94)
≥50 years	ref	0.63	(0.24, 1.61)	1.23	(0.40, 3.80)

^a Odds ratios are relative to all other groups within category (i.e. 229E vs not, 0 to 5 vs not)

Abbreviation: HCoV, human coronavirus.

Table 3: Household index cases^a by human coronavirus type and age group

	HCoV Type, N (column %)			
	229E	HKU1	NL63	OC43
Age groups				
0-5	13 (11.5)	38 (26.8)	45 (20.7)	82 (31.2)
6-11	21 (18.6)	35 (25.4)	78 (36.9)	65 (24.7)
12-17	16 (14.2)	9 (6.3)	24 (11.1)	24 (9.1)
18-49	54 (47.8)	56 (39.4)	64 (29.5)	83 (31.6)
50+	9 (8.0)	3 (2.1)	6 (2.8)	9 (3.4)

^a Only index cases from the first introduction of each coronavirus type to a household per season are included.

Abbreviation: HCoV, human coronavirus.

Figure 1. Counts of human coronavirus (HCoV) infections over 8 study years by type and month of illness onset: Household Influenza Vaccine Evaluation Study 2010-2018.

Figure 2. Incidence per 100 person-years of human coronavirus (HCoV) infections by type over 8 study years: Household Influenza Vaccine Evaluation Study 2010-2018. Error bars represent 95% confidence intervals.

Figure 3. Incidence per 100 person-years of human coronavirus (HCoV) infections by type and age group over 8 study years: Household Influenza Vaccine Evaluation Study 2010-2018. Error bars represent 95% confidence intervals.

Accepted Manuscript

Figure 1




Figure 2




Figure 3

